Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2019 Expert video Report on Neuroendocrine Tumours

Reporting from ESMO Congress 2019, Philippe Ruszniewski comments on results of 3 studies that evaluated the effects of the addition of radioembolisation to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumours (NETs), doubling a dose of lanreotide in patients with pancreatic or midgut NETs who progressed on conventional dosage, and the efficacy and safety of novel tyrosine kinase inhibitor surufatinib in well-differentiated advanced extrapancreatic NETs.


LBA76: Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized phase III study (SANET-ep)

1388P: Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.

1380O: 177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours; a single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.